Fourth Quarter Revenues Increase 7.5% to $450.5 million; up 6.9%
on Constant Currency Basis
Fourth Quarter GAAP Diluted EPS of $0.78; Adjusted Diluted EPS of
$1.36 up 18.3%
2014 Guidance Ranges for Constant Currency Revenue Growth of 7% to
9% and Adjusted Diluted EPS of $5.35 to $5.55 Reaffirmed
LIMERICK, Pa.--(BUSINESS WIRE)--Feb. 21, 2014--
Teleflex Incorporated (NYSE: TFX) today announced financial results for
the fourth quarter and full year ended December 31, 2013.
Fourth quarter 2013 net revenues were $450.5 million, an increase of
7.5% over the prior year period. Excluding the impact of foreign
currency fluctuations, fourth quarter 2013 net revenues increased 6.9%
over the prior year period.
Fourth quarter 2013 GAAP diluted earnings per share from continuing
operations were $0.78, as compared to $0.72 in the prior year period.
Fourth quarter 2013 adjusted diluted earnings per share from continuing
operations were $1.36, as compared to $1.15 in the prior year period, an
increase of 18.3%.
“Teleflex delivered a strong finish to 2013, both in terms of constant
currency revenue growth and adjusted earnings per share achievement,”
said Benson Smith, Chairman, President and Chief Executive Officer. “Our
fourth quarter performance was aided by the contribution from the
acquisitions of Vidacare and LMA International, an improvement in the
average selling price of products, the introduction of new products to
the marketplace and one additional shipping day in the quarter as
compared to the prior year period.”
Added Mr. Smith, “As we turn to 2014, Teleflex is well-positioned to
continue to exceed industry revenue growth rates and expand adjusted
operating margin and earnings per share due to recently concluded dealer
negotiations, the acquisition of Vidacare, the introduction of new
products to the market, and the continued integration of the LMA
business.”
FOURTH QUARTER NET REVENUE BY PRODUCT GROUP AND SEGMENT
Product Group Revenues
Critical Care fourth quarter 2013 net revenues were $316.7 million, an
increase of 10.6% compared to the prior year period. Excluding the
impact of foreign currency fluctuations, fourth quarter 2013 net
revenues increased 10.2% compared to the prior year period. The increase
in constant currency revenue was due to higher sales of anesthesia,
interventional, vascular and urology products. The growth in sales of
anesthesia products was primarily due to the contribution from the LMA
International business (“LMA”), which was acquired in October of 2012.
The growth in sales of vascular and interventional access products was
primarily due to the contribution from the Vidacare Corporation business
(“Vidacare”), which was acquired in December of 2013. Constant currency
sales growth was partially offset by a decline in sales of respiratory
products.
Surgical Care fourth quarter 2013 net revenues were $80.5 million, an
increase of 5.2% compared to the prior year period. Excluding the impact
of foreign currency fluctuations, fourth quarter 2013 net revenues
increased 4.0% compared to the prior year period. The increase in
constant currency revenue was due to higher sales of ligation, access
and suture products, partially offset by a decline in sales of general
surgical instrument and chest drainage products.
Cardiac Care fourth quarter 2013 net revenues were $19.2 million, a
decrease of 6.0% compared to the prior year period on both an
as-reported and constant currency basis. The decrease in revenue was due
to a decline in sales of intra-aortic balloon pumps.
OEM and Development Services (“OEM”) fourth quarter 2013 net revenues
were $34.1 million, a decrease of 4.8% compared to the prior year
period. Excluding the impact of foreign currency fluctuations, fourth
quarter 2013 net revenues decreased 5.7% compared to the prior year
period. The decrease in constant currency revenue was primarily due to a
decline in sales of catheter and performance fiber products.
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
% Increase/ (Decrease)
|
|
|
|
December 31,
2013
|
|
December 31,
2012
|
|
Constant
Currency
|
|
Foreign
Currency
|
|
Total
Change
|
|
|
|
(Dollars in millions)
|
|
|
|
|
|
|
|
Critical Care
|
|
$
|
316.7
|
|
$
|
286.5
|
|
10.2
|
%
|
|
0.4
|
%
|
|
10.6
|
%
|
|
Surgical Care
|
|
|
80.5
|
|
|
76.5
|
|
4.0
|
%
|
|
1.2
|
%
|
|
5.2
|
%
|
|
Cardiac Care
|
|
|
19.2
|
|
|
20.4
|
|
(6.0
|
%)
|
|
—
|
|
|
(6.0
|
%)
|
|
OEM
|
|
|
34.1
|
|
|
35.7
|
|
(5.7
|
%)
|
|
0.9
|
%
|
|
(4.8
|
%)
|
|
Total
|
|
$
|
450.5
|
|
$
|
419.1
|
|
6.9
|
%
|
|
0.6
|
%
|
|
7.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Revenues
Americas fourth quarter 2013 net revenues were $212.4 million, an
increase of 6.2% compared to the prior year period. Excluding the impact
of foreign currency fluctuations, fourth quarter 2013 net revenues
increased 6.6% compared to the prior year period. The increase in
constant currency revenue was largely due to LMA and Vidacare product
sales, new product sales and price increases, partially offset by lower
sales volume of existing products as compared to the fourth quarter of
2012.
EMEA fourth quarter 2013 net revenues were $144.9 million, an increase
of 9.2% compared to the prior year period. Excluding the impact of
foreign currency fluctuations, fourth quarter 2013 net revenues
increased 5.2% compared to the prior year period. The increase in
constant currency revenue was due to LMA and Vidacare product sales,
price increases including the benefit of selling direct to customers in
some markets versus selling to a third party distributor and higher
sales volume of existing products as compared to the fourth quarter of
2012.
Asia fourth quarter 2013 net revenues were $59.1 million, an increase of
17.1% compared to the prior year period. Excluding the impact of foreign
currency fluctuations, fourth quarter 2013 net revenues increased 21.6%
compared to the prior year period. The increase in constant currency
revenue was due to LMA product sales, higher sales volume of existing
products and price increases.
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
% Increase/ (Decrease)
|
|
|
|
December 31,
2013
|
|
December 31,
2012
|
|
Constant
Currency
|
|
Foreign
Currency
|
|
Total
Change
|
|
|
|
(Dollars in millions)
|
|
|
|
|
|
|
|
Americas
|
|
$
|
212.4
|
|
$
|
200.1
|
|
6.6
|
%
|
|
(0.4
|
%)
|
|
6.2
|
%
|
|
EMEA
|
|
|
144.9
|
|
|
132.8
|
|
5.2
|
%
|
|
4.0
|
%
|
|
9.2
|
%
|
|
Asia
|
|
|
59.1
|
|
|
50.5
|
|
21.6
|
%
|
|
(4.5
|
%)
|
|
17.1
|
%
|
|
OEM
|
|
|
34.1
|
|
|
35.7
|
|
(5.7
|
%)
|
|
0.9
|
%
|
|
(4.8
|
%)
|
|
Total
|
|
$
|
450.5
|
|
$
|
419.1
|
|
6.9
|
%
|
|
0.6
|
%
|
|
7.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
FULL YEAR RESULTS
Net revenues for the full year 2013 were $1.696 billion, an increase of
9.4% compared to the prior year period. Excluding the impact of foreign
currency fluctuations which had a positive impact of 0.4%, net revenues
for 2013 increased 9.0% compared to 2012.
GAAP diluted earnings per share from continuing operations were $3.46
for the full year 2013, as compared to a loss per share of ($4.47) in
the prior year period. The financial results for 2012 reflect a goodwill
impairment charge of $315.1 million, net of tax, or $7.71 per share,
incurred in the first quarter of 2012.
Adjusted diluted earnings per share from continuing operations for the
full year of 2013 were $5.03, an increase of 13.5% over the prior year.
OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS
Depreciation expense and amortization of intangible assets and deferred
financing costs for full year 2013 were $107.9 million compared to $94.9
million for the prior year period.
Cash and cash equivalents at December 31, 2013 were $432.0 million
compared to $337.0 million at December 31, 2012.
Net accounts receivable at December 31, 2013 were $295.3 million
compared to $298.0 million at December 31, 2012.
Net inventories at December 31, 2013 were $333.6 million compared to
$323.3 million at December 31, 2012.
Net debt obligations at December 31, 2013 were $902.7 million compared
to $692.7 million at December 31, 2012. During the fourth quarter of
2013, as a result of the Company meeting a contingent conversion
threshold related to the Company’s stock price, the Company’s
convertible notes have been classified as a current liability as of
December 31, 2013. The determination of whether or not the convertible
notes are convertible must continue to be performed on a quarterly basis
until maturity or conversion. Consequently, the convertible notes may
not be convertible in future quarters, and therefore may again be
classified as long-term debt, if the contingent conversion threshold is
not met in such quarters.
2014 OUTLOOK
The Company reaffirmed full year 2014 financial estimates as follows:
Constant currency revenue growth between 7% and 9% for the full year
2014.
Adjusted diluted earnings per share in the range of $5.35 to $5.55.
|
|
|
FORECASTED 2014 CONSTANT CURRENCY REVENUE GROWTH RECONCILIATION
|
|
|
|
|
|
Low
|
|
High
|
|
|
|
|
|
|
|
Forecasted 2014 GAAP revenue growth
|
|
6.0%
|
|
8.0%
|
|
|
|
|
|
|
|
Foreign exchange
|
|
1.0%
|
|
1.0%
|
|
|
|
|
|
|
|
Forecasted 2014 constant currency revenue growth
|
|
7.0%
|
|
9.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FORECASTED 2014 ADJUSTED EARNINGS PER SHARE RECONCILIATION
|
|
|
|
Low
|
|
High
|
|
|
|
|
|
|
|
Forecasted 2014 diluted earnings per share attributable to common
shareholders
|
|
$3.60
|
|
$3.75
|
|
|
|
|
|
|
|
Restructuring, impairment charges and special items, net of tax
|
|
$0.65
|
|
$0.70
|
|
|
|
|
|
|
|
Intangible amortization expense, net of tax
|
|
$0.93
|
|
$0.93
|
|
|
|
|
|
|
|
Amortization of debt discount on convertible notes, net of tax
|
|
$0.17
|
|
$0.17
|
|
|
|
|
|
|
|
Forecasted 2014 adjusted diluted earnings per share
|
|
$5.35
|
|
$5.55
|
|
|
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
As previously announced, Teleflex will comment on its financial results
on a conference call to be held today at 8:00 a.m. (ET). The call will
be available live and archived on the company’s website at www.teleflex.com
and the accompanying presentation will be posted prior to the call.
An audio replay will be available until February 28, 2014 at 11:59pm
(ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888
(International), Passcode: 68453301.
ADDITIONAL NOTES
Constant currency revenue and growth exclude the impact of translating
the results of international subsidiaries at different currency exchange
rates from period to period.
Certain financial information is presented on a rounded basis, which may
cause minor differences.
Product group results and commentary exclude the impact of discontinued
operations, items included in restructuring and impairment charges, and
losses and other charges set forth in the condensed consolidated
statements of income and in the Reconciliation of Consolidated Statement
of Income Items set forth below.
NOTES ON NON-GAAP FINANCIAL MEASURES
This press release includes certain non-GAAP financial measures, which
include:
Adjusted diluted earnings per share. This measure excludes, depending on
the period presented (i) the effect of charges associated with our
restructuring programs, as well as goodwill and other asset impairment
charges; (ii) loss on extinguishment of debt; (iii) the gain or loss on
sales of businesses and assets; (iv) losses and other charges related to
acquisition costs, the reversal of liabilities related to certain
contingent consideration arrangements and a previously announced stock
keeping unit rationalization program, the establishment of a litigation
reserve and a litigation verdict against the Company with respect to a
non-operating joint venture; (v) amortization of the debt discount on
the Company’s convertible notes; (vi) charges associated with the
amortization of additional interest expense related to an interest rate
swap terminated in 2011; (vii) intangible amortization expense; and
(viii) tax benefits resulting from the resolution of prior years’ tax
matters and the filing of prior years’ amended tax returns. In addition,
the calculation of diluted shares within adjusted earnings per share
gives effect to the anti-dilutive impact of the Company’s convertible
note hedge agreements, which reduce the potential economic dilution that
otherwise would occur upon conversion of the Company’s senior
subordinated convertible notes (under GAAP, the anti-dilutive impact of
the convertible note hedge agreements is not reflected in diluted
shares).
Constant currency revenue. This measure excludes the impact of
translating the results of international subsidiaries at different
currency exchange rates from period to period.
Management believes these measures are useful to investors because they
eliminate items that do not reflect Teleflex’s day-to-day operations. In
addition, management believes that the calculation of non-GAAP diluted
shares is useful to investors because it provides insight into the
offsetting economic effect of the convertible note hedge against
conversions of the convertible notes. Management uses these financial
measures for internal managerial purposes, when publicly providing
guidance on possible future results, and to assist in our evaluation of
period-to-period comparisons. These financial measures are presented in
addition to results presented in accordance with generally accepted
accounting principles (“GAAP”) and should not be relied upon as a
substitute for GAAP financial measures. Tables reconciling these
non-GAAP measures to the most directly comparable GAAP measures are set
forth below.
|
|
|
RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS
|
|
Dollars in millions, except per share amounts
|
|
|
|
Quarter Ended – December 31, 2013
|
|
|
|
|
|
Cost
of
goods
sold
|
|
Selling,
general and
administrative
expenses
|
|
Research and
development
expenses
|
|
Restructuring
and other
impairment
charges
|
|
Interest
expense,
net
|
|
Income
taxes
|
|
Net income
(loss)
attributable to
common
shareholders
from
continuing
operations
|
|
Diluted earnings
per share
available to
common
shareholders
|
|
Shares used in
calculation of
GAAP and
adjusted
earnings
per
share
|
|
GAAP Basis
|
|
$
|
225.6
|
|
$
|
143.8
|
|
$
|
17.9
|
|
$
|
9.2
|
|
$
|
14.2
|
|
$
|
4.6
|
|
|
$
|
35.1
|
|
|
$
|
0.78
|
|
|
45,033
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other impairment charges
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9.2
|
|
|
—
|
|
|
1.7
|
|
|
|
7.6
|
|
|
$
|
0.17
|
|
|
—
|
|
|
Losses and other charges (A)
|
|
|
0.3
|
|
|
8.2
|
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|
2.5
|
|
|
|
6.5
|
|
|
$
|
0.14
|
|
|
—
|
|
|
Amortization of debt discount on convertible notes
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.9
|
|
|
1.1
|
|
|
|
1.8
|
|
|
$
|
0.04
|
|
|
—
|
|
|
Intangible amortization expense
|
|
|
—
|
|
|
13.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.5
|
|
|
|
9.0
|
|
|
$
|
0.20
|
|
|
—
|
|
|
Tax Adjustment (B)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.5
|
|
|
|
(1.5
|
)
|
|
|
($0.03
|
)
|
|
—
|
|
|
Shares due to Teleflex under note hedge (C)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
$
|
0.06
|
|
|
(2,165
|
)
|
|
Adjusted basis
|
|
$
|
225.3
|
|
$
|
122.0
|
|
$
|
17.3
|
|
|
—
|
|
$
|
11.3
|
|
$
|
15.8
|
|
|
$
|
58.5
|
|
|
$
|
1.36
|
|
|
42,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended - December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of
goods
sold
|
|
Selling,
general and
administrative
expenses
|
|
Research and
development
expenses
|
|
Restructuring
and other
impairment
charges
|
|
Interest
expense,
net
|
|
Income
taxes
|
|
Net income
(loss)
attributable to
common
shareholders
from
continuing
operations
|
|
Diluted earnings
per share
available to
common
shareholders
|
|
Shares used in
calculation of
GAAP and
adjusted
earnings
per
share
|
|
GAAP Basis
|
|
$
|
219.9
|
|
$
|
121.5
|
|
$
|
16.3
|
|
$
|
3.0
|
|
$
|
14.4
|
|
$
|
13.5
|
|
|
$
|
30.4
|
|
|
$
|
0.72
|
|
|
42,007
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other impairment charges
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.0
|
|
|
—
|
|
|
0.6
|
|
|
|
2.3
|
|
|
$
|
0.06
|
|
|
—
|
|
|
Losses and other charges (A)
|
|
|
0.5
|
|
|
3.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.9
|
)
|
|
|
5.4
|
|
|
$
|
0.13
|
|
|
—
|
|
|
Amortization of debt discount on convertible notes
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.7
|
|
|
1.0
|
|
|
|
1.7
|
|
|
$
|
0.04
|
|
|
—
|
|
|
Intangible amortization expense
|
|
|
—
|
|
|
12.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.2
|
|
|
|
7.8
|
|
|
$
|
0.19
|
|
|
—
|
|
|
Tax adjustment (B)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
Shares due to Teleflex under note hedge (C)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
$
|
0.02
|
|
|
(733
|
)
|
|
Adjusted basis
|
|
$
|
219.4
|
|
$
|
106.5
|
|
$
|
16.3
|
|
|
—
|
|
$
|
11.7
|
|
$
|
17.3
|
|
|
$
|
47.6
|
|
|
$
|
1.15
|
|
|
41,274
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(A) In 2013, losses and other charges include approximately $4.0
million, net of tax, or $0.09 per share, primarily related to
acquisition and integration costs; $1.9 million, net of tax, or
$0.04 per share related to the establishment of a litigation
reserve; and $0.6 million, net of tax, or $0.01 per share related to
costs incurred to relocate facilities. In 2012, losses and other
charges include approximately $5.4 million, net of tax, or $0.13 per
share, related to acquisition costs.
|
|
|
|
(B) The tax adjustment represents a net benefit resulting from the
resolution of, or the expiration of statute of limitations with
respect to various prior years’ U.S. federal, state and foreign tax
matters.
|
|
|
|
(C) Adjusted diluted shares are calculated by giving effect to the
anti-dilutive impact of the Company’s convertible note hedge
agreements, which reduce the potential economic dilution that
otherwise would occur upon conversion of our senior subordinated
convertible notes. Under GAAP, the anti-dilutive impact of the
convertible note hedge agreements is not reflected in diluted shares.
|
|
|
|
|
|
RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS
|
|
Dollars in millions, except per share amounts
|
|
|
|
Twelve Months Ended – December 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of
goods
sold
|
|
Selling,
general and
administrative
expenses
|
|
Research and
development
expenses
|
|
Goodwill
impairment
|
|
Restructuring
and other
impairment
charges
|
|
Gain/(loss)
on sales of
businesses
and
assets
|
|
Loss on
extinguishment
of debt
|
|
Interest
expense,
net
|
|
Income
taxes
|
|
Net income
(loss) attributable
to common
shareholders
from
continuing
operations
|
|
Diluted
earnings per
share available
to
common
shareholders
|
|
Shares used
in calculation
of GAAP and
adjusted
earnings
per
share
|
|
GAAP Basis
|
|
$
|
857.3
|
|
$
|
502.2
|
|
$
|
65.0
|
|
|
—
|
|
$
|
38.5
|
|
|
—
|
|
|
$
|
1.3
|
|
$
|
56.3
|
|
$
|
23.5
|
|
$
|
151.3
|
|
|
$
|
3.46
|
|
|
43,693
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other impairment charges
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
38.5
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
7.8
|
|
|
30.7
|
|
|
$
|
0.71
|
|
|
—
|
|
|
Loss on extinguishment of debt
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
1.3
|
|
|
—
|
|
|
0.5
|
|
|
0.8
|
|
|
$
|
0.02
|
|
|
—
|
|
|
Losses and other charges (A)
|
|
|
2.3
|
|
|
1.5
|
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|
(0.6
|
)
|
|
|
($0.02
|
)
|
|
—
|
|
|
Amortization of debt discount on convertible notes
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
11.3
|
|
|
4.1
|
|
|
7.2
|
|
|
$
|
0.16
|
|
|
—
|
|
|
Intangible amortization expense
|
|
|
—
|
|
|
50.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
17.3
|
|
|
33.4
|
|
|
$
|
0.76
|
|
|
—
|
|
|
Tax Adjustment (D)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
11.1
|
|
|
(11.1
|
)
|
|
|
($0.25
|
)
|
|
—
|
|
|
Shares due to Teleflex under note hedge (E)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
$
|
0.19
|
|
|
(1,620
|
)
|
|
Adjusted basis
|
|
$
|
855.1
|
|
$
|
450.1
|
|
$
|
64.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
$
|
45.0
|
|
$
|
69.2
|
|
$
|
211.6
|
|
|
$
|
5.03
|
|
|
42,073
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended - December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of
goods
sold
|
|
Selling,
general and
administrative
expenses
|
|
Research and
development
expenses
|
|
Goodwill
impairment
|
|
Restructuring
and other
impairment
charges
|
|
Gain/(loss)
on sales of
businesses
and
assets
|
|
Loss on
extinguishment
of debt
|
|
Interest
expense,
net
|
|
Income
taxes
|
|
Net income
(loss) attributable
to common
shareholders
from
continuing
operations
|
|
Diluted
earnings per
share available
to
common
shareholders
|
|
Shares used
in calculation
of GAAP and
adjusted
earnings
per
share
|
|
GAAP Basis
|
|
$
|
802.8
|
|
$
|
454.5
|
|
$
|
56.3
|
|
$
|
332.1
|
|
$
|
3.0
|
|
$
|
0.3
|
|
|
|
—
|
|
$
|
68.0
|
|
$
|
16.4
|
|
|
($182.7
|
)
|
|
|
($4.47
|
)
|
|
40,859
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill impairment
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
332.1
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
17.0
|
|
|
315.1
|
|
|
$
|
7.71
|
|
|
—
|
|
|
Restructuring and other impairment charges
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.0
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
0.6
|
|
|
2.5
|
|
|
$
|
0.06
|
|
|
—
|
|
|
Gain/(loss) on sales of businesses and assets
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.3
|
)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.3
|
)
|
|
|
($0.01
|
)
|
|
—
|
|
|
Loss on extinguish-
ment of debt
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
Losses and other charges (A)
|
|
|
0.5
|
|
|
14.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
14.6
|
|
|
$
|
0.36
|
|
|
—
|
|
|
Early termination of interest rate swap (B)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
11.1
|
|
|
4.0
|
|
|
7.0
|
|
|
$
|
0.17
|
|
|
—
|
|
|
Amortization of debt discount on convertible notes
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
10.5
|
|
|
3.8
|
|
|
6.7
|
|
|
$
|
0.16
|
|
|
—
|
|
|
Intangible amortization expense
|
|
|
—
|
|
|
44.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
16.0
|
|
|
28.3
|
|
|
$
|
0.69
|
|
|
—
|
|
|
Anti-dilutive effect on EPS (C)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
($0.06
|
)
|
|
542
|
|
|
Tax adjustment (D)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
9.0
|
|
|
(9.0
|
)
|
|
|
($0.22
|
)
|
|
—
|
|
|
Shares due to Teleflex under note hedge (E)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
$
|
0.03
|
|
|
(275
|
)
|
|
Adjusted basis
|
|
$
|
802.3
|
|
$
|
396.0
|
|
$
|
56.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
$
|
46.5
|
|
$
|
66.7
|
|
$
|
182.2
|
|
|
$
|
4.43
|
|
|
41,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(A) In 2013, losses and other charges include approximately ($12.4)
million, net of tax, or ($0.28) per share, related to the reversal
of contingent consideration liabilities; $7.8 million, net of tax,
or $0.18 per share, primarily related to acquisition and integration
costs; ($0.3) million, net of tax, or ($0.01) per share, related to
a reserve reversal associated with a previously announced stock
keeping unit (“SKU”) rationalization charge; $0.8 million, net of
tax, or $0.02 per share, related to a litigation verdict against the
Company with respect to a non-operating joint venture; $1.9 million,
net of tax, or $0.04 per share related to the establishment of a
litigation reserve; and $1.6 million, net of tax, or $0.04 per share
related to costs incurred to relocate facilities. In 2012, losses
and other charges include approximately $0.2 million, net of tax
related to contingent consideration liabilities; and $14.4 million,
net of tax, or $0.36 per share, related to acquisition costs.
|
|
|
|
(B) In 2011, the Company terminated an interest rate swap that, at
the date of termination, had a notional amount of $350 million. The
interest rate swap was designated as a cash flow hedge against the
term loan under our senior credit facility. At the date of
termination, the interest rate swap was in a liability position
resulting in a cash payment by the Company to the counterparty of
approximately $14.8 million, which included $3.1 million of accrued
interest. In accordance with GAAP, the Company amortized this amount
as additional interest expense over the remainder of the original
term of the interest rate swap, which expired in September 2012. In
the first nine months of 2012, the impact of the amortization, net
of tax, was approximately $7.0 million, or $0.17 per share.
|
|
|
|
(C) The Company presents per share results using basic weighted
average shares, and separately presents diluted per share results,
which reflect with the impact of dilution on income. Under
applicable accounting guidance, if a company has a net loss from
continuing operations, as was the case for the Company in 2012, no
common shares that potentially may be issued are included in the
computation of diluted per-share amounts because such inclusion
would result in an anti-dilutive per share amount. However, the
Company had net income on an adjusted basis in 2012. Therefore,
common shares that would have a dilutive effect on adjusted net
income are deemed to be outstanding for purposes of the calculation
of 2012 adjusted diluted earnings per share.
|
|
|
|
(D) The tax adjustment represents a net benefit resulting from the
resolution of, or the expiration of statutes of limitations with
respect to various prior years’ U.S. federal, state and foreign tax
matters.
|
|
|
|
(E) Adjusted diluted shares are calculated by including the
anti-dilutive impact of the Company’s convertible note hedge
agreements, which reduce the potential economic dilution that
otherwise would occur upon conversion of our senior subordinated
convertible notes. Under GAAP, the anti-dilutive impact of the
convertible note hedge agreements is not reflected in diluted shares.
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF NET DEBT OBLIGATIONS
|
|
|
|
|
|
|
|
|
|
December 31, 2013
|
|
December 31, 2012
|
|
|
|
(Dollars in thousands)
|
|
Note payable and current portion of long-term borrowings
|
|
$
|
356,287
|
|
$
|
4,700
|
|
|
|
|
|
|
|
Long term borrowings
|
|
|
930,000
|
|
|
965,280
|
|
|
|
|
|
|
|
Unamortized debt discount
|
|
|
48,413
|
|
|
59,720
|
|
|
|
|
|
|
|
Total debt obligations
|
|
|
1,334,700
|
|
|
1,029,700
|
|
|
|
|
|
|
|
Less: cash and cash equivalents
|
|
|
431,984
|
|
|
337,039
|
|
|
|
|
|
|
|
Net debt obligations
|
|
$
|
902,716
|
|
$
|
692,661
|
|
|
|
|
|
|
|
|
ABOUT TELEFLEX INCORPORATED
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,400 people worldwide and serves
healthcare providers in more than 150 countries. For additional
information about Teleflex please refer to www.teleflex.com.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but
not limited to, forecasted 2014 GAAP and constant currency revenue
growth and GAAP and adjusted diluted earnings per share and the
anticipated expansion of operating margins and earnings per share as a
result of recently concluded dealer negotiations, the acquisition of
Vidacare, the introduction of new products to the market and the
continued integration of the LMA business. Actual results could differ
materially from those in the forward-looking statements due to, among
other things, conditions in the end markets we serve, customer reaction
to new products and programs, our ability to achieve sales growth, price
increases or cost reductions; changes in the reimbursement practices of
third party payors; our ability to realize efficiencies and to execute
on our strategic initiatives; changes in material costs and surcharges;
market acceptance and unanticipated difficulties in connection with the
introduction of new products and product line extensions; product
recalls; unanticipated difficulties in connection with the consolidation
of manufacturing and administrative functions; unanticipated
difficulties, expenditures and delays in complying with government
regulations applicable to our businesses; the impact of government
healthcare reform legislation; our ability to meet our debt obligations;
changes in general and international economic conditions; and other
factors described or incorporated in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the
year ended December 31, 2012.
|
|
|
TELEFLEX INCORPORATED AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF INCOME
|
|
|
|
|
|
Three Months Ended
|
|
|
|
December 31,
|
|
December 31,
|
|
|
|
2013
|
|
2012
|
|
|
|
(Dollars and shares in thousands,
|
|
|
|
except per share)
|
|
|
|
|
|
|
|
Net revenues
|
|
$
|
450,539
|
|
|
$
|
419,056
|
|
|
Cost of goods sold
|
|
|
225,596
|
|
|
|
219,876
|
|
|
Gross profit
|
|
|
224,943
|
|
|
|
199,180
|
|
|
Selling, general and administrative expenses
|
|
|
143,756
|
|
|
|
121,524
|
|
|
Research and development expenses
|
|
|
17,876
|
|
|
|
16,263
|
|
|
Restructuring and other impairment charges
|
|
|
9,247
|
|
|
|
2,953
|
|
|
Income from continuing operations before interest and taxes
|
|
|
54,064
|
|
|
|
58,440
|
|
|
Interest expense
|
|
|
14,339
|
|
|
|
14,621
|
|
|
Interest income
|
|
|
(166
|
)
|
|
|
(247
|
)
|
|
Income from continuing operations before taxes
|
|
|
39,891
|
|
|
|
44,066
|
|
|
Taxes on income from continuing operations
|
|
|
4,589
|
|
|
|
13,452
|
|
|
Income from continuing operations
|
|
|
35,302
|
|
|
|
30,614
|
|
|
Operating loss from discontinued operations (including loss on
disposal of $21 in 2012)
|
|
|
(459
|
)
|
|
|
(1,256
|
)
|
|
Tax benefit on loss from discontinued operations
|
|
|
(223
|
)
|
|
|
(219
|
)
|
|
Loss from discontinued operations
|
|
|
(236
|
)
|
|
|
(1,037
|
)
|
|
Net income
|
|
|
35,066
|
|
|
|
29,577
|
|
|
Less: Income from continuing operations attributable to
noncontrolling interest
|
|
|
238
|
|
|
|
254
|
|
|
Net income attributable to common shareholders
|
|
$
|
34,828
|
|
|
$
|
29,323
|
|
|
|
|
|
|
|
|
Earnings per share available to common shareholders:
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.85
|
|
|
$
|
0.74
|
|
|
Loss from discontinued operations
|
|
|
—
|
|
|
|
(0.02
|
)
|
|
Net income
|
|
$
|
0.85
|
|
|
$
|
0.72
|
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.78
|
|
|
$
|
0.72
|
|
|
Loss from discontinued operations
|
|
|
(0.01
|
)
|
|
|
(0.02
|
)
|
|
Net income
|
|
$
|
0.77
|
|
|
$
|
0.70
|
|
|
|
|
|
|
|
|
Dividends per common share
|
|
$
|
0.34
|
|
|
$
|
0.34
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
Basic
|
|
|
41,161
|
|
|
|
40,945
|
|
|
Diluted
|
|
|
45,033
|
|
|
|
42,007
|
|
|
|
|
|
|
|
|
Amounts attributable to common shareholders:
|
|
|
|
|
|
Income from continuing operations, net of tax
|
|
$
|
35,064
|
|
|
$
|
30,360
|
|
|
Loss from discontinued operations, net of tax
|
|
|
(236
|
)
|
|
|
(1,037
|
)
|
|
Net income
|
|
$
|
34,828
|
|
|
$
|
29,323
|
|
|
|
|
|
|
TELEFLEX INCORPORATED AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF INCOME (LOSS)
|
|
|
|
|
|
Twelve Months Ended
|
|
|
|
December 31,
|
|
December 31,
|
|
|
|
2013
|
|
2012
|
|
|
|
(Dollars and shares in thousands,
|
|
|
|
except per share)
|
|
|
|
|
|
|
|
Net revenues
|
|
$
|
1,696,271
|
|
|
$
|
1,551,009
|
|
|
Cost of goods sold
|
|
|
857,326
|
|
|
|
802,784
|
|
|
Gross profit
|
|
|
838,945
|
|
|
|
748,225
|
|
|
Selling, general and administrative expenses
|
|
|
502,187
|
|
|
|
454,489
|
|
|
Research and development expenses
|
|
|
65,045
|
|
|
|
56,278
|
|
|
Goodwill impairment
|
|
|
—
|
|
|
|
332,128
|
|
|
Restructuring and other impairment charges
|
|
|
38,452
|
|
|
|
3,037
|
|
|
Gain on sales of businesses and assets
|
|
|
—
|
|
|
|
(332
|
)
|
|
Income (loss) from continuing operations before interest, loss on
extinguishments of debt and taxes
|
|
|
233,261
|
|
|
|
(97,375
|
)
|
|
Interest expense
|
|
|
56,905
|
|
|
|
69,565
|
|
|
Interest income
|
|
|
(624
|
)
|
|
|
(1,571
|
)
|
|
Loss on extinguishments of debt
|
|
|
1,250
|
|
|
|
—
|
|
|
Income (loss) from continuing operations before taxes
|
|
|
175,730
|
|
|
|
(165,369
|
)
|
|
Taxes on income (loss) from continuing operations
|
|
|
23,547
|
|
|
|
16,413
|
|
|
Income (loss) from continuing operations
|
|
|
152,183
|
|
|
|
(181,782
|
)
|
|
Operating loss from discontinued operations (including gain on
disposal of $2,205 in 2012)
|
|
|
(2,205
|
)
|
|
|
(9,207
|
)
|
|
Tax benefit on loss from discontinued operations
|
|
|
(1,770
|
)
|
|
|
(1,887
|
)
|
|
Loss from discontinued operations
|
|
|
(435
|
)
|
|
|
(7,320
|
)
|
|
Net income (loss)
|
|
|
151,748
|
|
|
|
(189,102
|
)
|
|
Less: Income from continuing operations attributable to
noncontrolling interest
|
|
|
867
|
|
|
|
955
|
|
|
Net income (loss) attributable to common shareholders
|
|
$
|
150,881
|
|
|
$
|
(190,057
|
)
|
|
|
|
|
|
|
|
Earnings per share available to common shareholders:
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
3.68
|
|
|
$
|
(4.47
|
)
|
|
Loss from discontinued operations
|
|
|
(0.01
|
)
|
|
|
(0.18
|
)
|
|
Net income (loss)
|
|
$
|
3.67
|
|
|
$
|
(4.65
|
)
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
3.46
|
|
|
$
|
(4.47
|
)
|
|
Loss from discontinued operations
|
|
|
(0.01
|
)
|
|
|
(0.18
|
)
|
|
Net income (loss)
|
|
$
|
3.45
|
|
|
$
|
(4.65
|
)
|
|
|
|
|
|
|
|
Dividends per common share
|
|
$
|
1.36
|
|
|
$
|
1.36
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
Basic
|
|
|
41,105
|
|
|
|
40,859
|
|
|
Diluted
|
|
|
43,693
|
|
|
|
40,859
|
|
|
|
|
|
|
|
|
Amounts attributable to common shareholders:
|
|
|
|
|
|
Income (loss) from continuing operations, net of tax
|
|
$
|
151,316
|
|
|
$
|
(182,737
|
)
|
|
Loss from discontinued operations, net of tax
|
|
|
(435
|
)
|
|
|
(7,320
|
)
|
|
Net income (loss)
|
|
$
|
150,881
|
|
|
$
|
(190,057
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TELEFLEX INCORPORATED AND SUBSIDIARIES
|
|
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
December 31,
|
|
|
|
2013
|
|
2012
|
|
|
|
(Dollars in thousands)
|
|
ASSETS
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
431,984
|
|
|
$
|
337,039
|
|
|
Accounts receivable, net
|
|
|
295,290
|
|
|
|
297,976
|
|
|
Inventories, net
|
|
|
333,621
|
|
|
|
323,347
|
|
|
Prepaid expenses and other current assets
|
|
|
39,810
|
|
|
|
28,712
|
|
|
Prepaid taxes
|
|
|
36,504
|
|
|
|
27,160
|
|
|
Deferred tax assets
|
|
|
52,917
|
|
|
|
51,025
|
|
|
Assets held for sale
|
|
|
10,428
|
|
|
|
7,963
|
|
|
Total current assets
|
|
|
1,200,554
|
|
|
|
1,073,222
|
|
|
Property, plant and equipment, net
|
|
|
325,900
|
|
|
|
297,945
|
|
|
Goodwill
|
|
|
1,354,203
|
|
|
|
1,238,452
|
|
|
Intangible assets, net
|
|
|
1,255,597
|
|
|
|
1,058,792
|
|
|
Investments in affiliates
|
|
|
1,715
|
|
|
|
2,066
|
|
|
Deferred tax assets
|
|
|
943
|
|
|
|
1,347
|
|
|
Other assets
|
|
|
70,095
|
|
|
|
61,863
|
|
|
Total assets
|
|
$
|
4,209,007
|
|
|
$
|
3,733,687
|
|
|
|
|
|
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Notes payable
|
|
$
|
356,287
|
|
|
$
|
4,700
|
|
|
Accounts payable
|
|
|
71,967
|
|
|
|
75,165
|
|
|
Accrued expenses
|
|
|
74,868
|
|
|
|
65,064
|
|
|
Current portion of contingent consideration
|
|
|
4,131
|
|
|
|
23,693
|
|
|
Payroll and benefit-related liabilities
|
|
|
73,090
|
|
|
|
74,586
|
|
|
Accrued interest
|
|
|
8,725
|
|
|
|
9,418
|
|
|
Income taxes payable
|
|
|
23,821
|
|
|
|
16,895
|
|
|
Other current liabilities
|
|
|
22,231
|
|
|
|
5,779
|
|
|
Total current liabilities
|
|
|
635,120
|
|
|
|
275,300
|
|
|
Long-term borrowings
|
|
|
930,000
|
|
|
|
965,280
|
|
|
Deferred tax liabilities
|
|
|
514,715
|
|
|
|
418,874
|
|
|
Pension and postretirement benefit liabilities
|
|
|
109,498
|
|
|
|
170,946
|
|
|
Noncurrent liability for uncertain tax positions
|
|
|
55,152
|
|
|
|
61,979
|
|
|
Other liabilities
|
|
|
48,506
|
|
|
|
59,771
|
|
|
Total liabilities
|
|
|
2,292,991
|
|
|
|
1,952,150
|
|
|
Common shareholders’ equity
|
|
|
|
|
|
Common shares, $1 par value Issued: 2013 — 43,243 shares; 2012 —
43,102 shares
|
|
|
43,243
|
|
|
|
43,102
|
|
|
Additional paid-in capital
|
|
|
409,338
|
|
|
|
394,384
|
|
|
Retained earnings
|
|
|
1,696,424
|
|
|
|
1,601,460
|
|
|
Accumulated other comprehensive loss
|
|
|
(110,855
|
)
|
|
|
(132,048
|
)
|
|
|
|
|
2,038,150
|
|
|
|
1,906,898
|
|
|
Less: Treasury stock, at cost
|
|
|
124,623
|
|
|
|
127,948
|
|
|
Total common shareholders’ equity
|
|
|
1,913,527
|
|
|
|
1,778,950
|
|
|
Noncontrolling interest
|
|
|
2,489
|
|
|
|
2,587
|
|
|
Total equity
|
|
|
1,916,016
|
|
|
|
1,781,537
|
|
|
Total liabilities and equity
|
|
$
|
4,209,007
|
|
|
$
|
3,733,687
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TELEFLEX INCORPORATED AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
Twelve Months Ended
|
|
|
|
December 31,
|
|
December 31,
|
|
|
|
2013
|
|
2012
|
|
|
|
(Dollars in thousands)
|
|
Cash Flows from Operating Activities of Continuing Operations:
|
|
|
|
|
|
Net income (loss)
|
|
$
|
151,748
|
|
|
$
|
(189,102
|
)
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
Loss from discontinued operations
|
|
|
435
|
|
|
|
7,320
|
|
|
Depreciation expense
|
|
|
42,368
|
|
|
|
36,204
|
|
|
Amortization expense of intangible assets
|
|
|
50,608
|
|
|
|
44,264
|
|
|
Amortization expense of deferred financing costs and debt discount
|
|
|
14,959
|
|
|
|
14,416
|
|
|
Loss on extinguishments of debt
|
|
|
1,250
|
|
|
|
—
|
|
|
Impairment of long-lived assets
|
|
|
3,460
|
|
|
|
—
|
|
|
In-process research and development impairment
|
|
|
7,381
|
|
|
|
—
|
|
|
Change in contingent consideration
|
|
|
(12,642
|
)
|
|
|
263
|
|
|
Stock-based compensation
|
|
|
11,871
|
|
|
|
8,623
|
|
|
Gain on sales of businesses and assets
|
|
|
—
|
|
|
|
(332
|
)
|
|
Goodwill impairment
|
|
|
—
|
|
|
|
332,128
|
|
|
Deferred income taxes, net
|
|
|
(8,925
|
)
|
|
|
(39,178
|
)
|
|
Other
|
|
|
(8,700
|
)
|
|
|
(3,776
|
)
|
|
Changes in operating assets and liabilities, net of effects of
acquisitions and disposals:
|
|
|
|
|
|
Accounts receivable
|
|
|
(1,294
|
)
|
|
|
(2,932
|
)
|
|
Inventories
|
|
|
(8,931
|
)
|
|
|
(1,970
|
)
|
|
Prepaid expenses and other current assets
|
|
|
(5,926
|
)
|
|
|
9,595
|
|
|
Accounts payable and accrued expenses
|
|
|
(684
|
)
|
|
|
(1,412
|
)
|
|
Income taxes receivable and payable, net
|
|
|
(7,107
|
)
|
|
|
(20,258
|
)
|
|
Net cash provided by operating activities from continuing operations
|
|
|
229,871
|
|
|
|
193,853
|
|
|
Cash Flows from Investing Activities of Continuing Operations:
|
|
|
|
|
|
Expenditures for property, plant and equipment
|
|
|
(63,580
|
)
|
|
|
(65,394
|
)
|
|
Payments for businesses and intangibles acquired, net of cash
acquired
|
|
|
(309,008
|
)
|
|
|
(369,444
|
)
|
|
Proceeds from sales of businesses and assets, net of cash sold
|
|
|
—
|
|
|
|
66,660
|
|
|
Investments in affiliates
|
|
|
(50
|
)
|
|
|
(80
|
)
|
|
Net cash used in investing activities from continuing operations
|
|
|
(372,638
|
)
|
|
|
(368,258
|
)
|
|
Cash Flows from Financing Activities of Continuing Operations:
|
|
|
|
|
|
Proceeds from long-term borrowings
|
|
|
680,000
|
|
|
|
—
|
|
|
Repayment of long-term borrowings
|
|
|
(375,000
|
)
|
|
|
—
|
|
|
Debt extinguishment, issuance and amendment fees
|
|
|
(6,400
|
)
|
|
|
—
|
|
|
Decrease in notes payable and current borrowings
|
|
|
—
|
|
|
|
(706
|
)
|
|
Proceeds from stock compensation plans
|
|
|
7,609
|
|
|
|
9,003
|
|
|
Payments to noncontrolling interest shareholders
|
|
|
(736
|
)
|
|
|
—
|
|
|
Payments for contingent consideration
|
|
|
(16,958
|
)
|
|
|
(17,596
|
)
|
|
Dividends
|
|
|
(55,917
|
)
|
|
|
(55,589
|
)
|
|
Net cash provided by (used in) financing activities from continuing
operations
|
|
|
232,598
|
|
|
|
(64,888
|
)
|
|
Cash Flows from Discontinued Operations:
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(3,327
|
)
|
|
|
(7,799
|
)
|
|
Net cash used in investing activities
|
|
|
—
|
|
|
|
(2,351
|
)
|
|
Net cash used in discontinued operations
|
|
|
(3,327
|
)
|
|
|
(10,150
|
)
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
8,441
|
|
|
|
2,394
|
|
|
Net increase (decrease) increase in cash and cash equivalents
|
|
|
94,945
|
|
|
|
(247,049
|
)
|
|
Cash and cash equivalents at the beginning of the period
|
|
|
337,039
|
|
|
|
584,088
|
|
|
Cash and cash equivalents at the end of the period
|
|
$
|
431,984
|
|
|
$
|
337,039
|
|
|
|
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President of Investor Relations
610-948-2836